Bluejay Announces Receipt of PRIME Designation from European Medicines Agency (EMA) for BJT-778 for the Treatment of Chronic Hepatitis Delta Virus Infection
Currently Enrolling Phase 2 Study of BJT-778 in HDV; Interim Data Expected second half of 2024SAN MATEO, Calif., March 25,...